EHT 1610 is a potent inhibitor ofDYRK, withIC₅₀sof 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cellapoptosis^[1]-[4].

IC50: 0.36 nM (DYRK1A), 0.59 nM (DYRK1B)^[1]

EHT 1610 induces apoptosis of primary ALL cells that were resistant to cytarabine^[2].
EHT 1610 dose-dependently induces apoptosis in B- and T-cell lines and primary human pediatric^[2].
EHT 1610 (; 72 h) inhibits DYRK1A, results loss of DYRK1A-mediated FOXO1 and STAT3 signaling, leading to preferential cell death in leukemic B cells^[3].
EHT 1610 (2.5-10 μM; 4-5 h) inhibits phosphorylation of FOXO1, STAT3 and cyclin D3, thus regulates late cell-cycle progression, mitochondrial ROS and DNA damage, respectively^[3].

EHT 1610 (20 mg/kg/d; i.p.; twice a day; 3 weeks) shows antileukemia activity against in leukemic aggressive model in mice^[3].

383.40

Solid

C₁₈H₁₄FN₅O₂S

1425945-60-3

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light, stored under nitrogen

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

DMSO : 5 mg/mL(13.04 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。